The Horizon trial is evaluating whether lowering Lipoprotein(a) with pelacarsen translates into a reduction in major adverse cardiovascular events (MACE) in high-risk individuals.

Every Sunday: the week’s new conflicts and verdict changes — and nothing else.

Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.